OncoMatch/Clinical Trials/NCT07250269
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Is NCT07250269 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies GC012F for relapsed/refractory al amyloidosis.
Treatment: GC012F — This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Excluded: Stage MAYO STAGE IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-plasma cell-directed therapy
need for additional therapy after at least 1 line of anti-plasma cell-directed therapy
Cannot have received: CAR-T cell therapy
Prior CAR T cell therapy directed at any target
Cannot have received: BCMA-targeting therapy
Prior BCMA-targeting therapy
Cannot have received: T cell engaging therapy
Exception: within the last 6 months
Prior treatment with any approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months
Lab requirements
Cardiac function
NT-proBNP ≥ 2000 ng/L (for dose escalation portion); NT-proBNP < 2000 and > 5000 ng/L (for dose extension portion); High-sensitivity cardiac troponin T > 75 ng/L; NYHA class III or IV; Systolic blood pressure <100mmHg; Oxygen saturation < 95% on room air
NT-proBNP levels as follows: NT-proBNP ≥ 2000 ng/L (for dose escalation portion) NT-proBNP < 2000 and > 5000 ng/L (for dose extension portion) High-sensitivity cardiac troponin T > 75 ng/L NYHA class III or IV Systolic blood pressure <100mmHg Oxygen saturation < 95% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07250269 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, BCMA-targeting therapy, T cell engaging therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages